Clinical Advances in Hormone Receptor-Positive Breast Cancer
Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, discuss systemic therapy and recent clinical trial data presented at the 2021 ASCO Annual Meeting for hormone receptor-positive breast cancer.
EP. 1: Role of Molecular Profiling in HR+ Metastatic Breast Cancer
Aditya Bardia, MD, MPH, Massachusetts General Hospital
Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, discuss when it is appropriate to order molecular testing and the impact of testing on the treatment of HR-positive metastatic breast cancer.
EP. 2: Management of HR+ mBC: Key Prognostic Factors
Aditya Bardia, MD, MPH, Massachusetts General Hospital
Considerations for approaching the treatment of HR-positive metastatic breast cancer through insights on key prognostic factors.
EP. 3: Using CDK4/6 Inhibitors in First-Line Treatment of HR+ mBC
Aditya Bardia, MD, Massachusetts General Hospital Cancer Center
A review of data from key phase 3 clinical trials, including ASCO 2021 updates, assessing the use of CDK4/6 inhibitors with endocrine therapy for the frontline treatment of HR-positive metastatic breast cancer.
EP. 4: Selecting a CDK4/6 Inhibitor for HR+ mBC
Aditya Bardia, MD, Massachusetts General Hospital Cancer Center
Experts in breast cancer comment on the appropriate patient selection of CDK4/6 inhibitors for the management of HR-positive metastatic breast cancer.
EP. 6: Case Discussion: Resistance to CDK4/6 Inhibitors in HR+ mBC
Aditya Bardia, MD, Massachusetts General Hospital Cancer Center
Andrew D. Seidman, MD, presents a case study of a 56-year-old postmenopausal woman diagnosed with stage IIB HR+ breast cancer and leads the discussion on approaching treatment for the given patient.
EP. 7: Using CDK4/6 Inhibitors After HR+ mBC Disease Progression
Aditya Bardia, MD, Massachusetts General Hospital Cancer Center
Breast cancer experts comment on whether there is a benefit to switching to or continuing on CDK4/6 inhibitors with disease progression for HR+ metastatic breast cancer and discuss the use of tamoxifen for third-line endocrine therapy.
EP. 8: PI3KCA Inhibition: Managing AEs in HR+ mBC
Aditya Bardia, MD, Massachusetts General Hospital Cancer Center
Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, review the optimal management of adverse events associated with alpelisib in HR+ metastatic breast cancer.
EP. 9: Emerging Agents for the Management of HR+ mBC
Aditya Bardia, MD, Massachusetts General Hospital Cancer Center
Aditya Bardia, MD, MPH, leads the discussion on the use of novel CDK4/6 inhibitors, BCL2 inhibitors, and oral SERDS for the treatment of HR+ metastatic breast cancer.
EP. 10: Using Genomic Assays for Early Stage HR+ Breast Cancer
Aditya Bardia, MD, Massachusetts General Hospital Cancer Center
The role of genomic assays, including Oncotype DX as reported on in the RxPONDER trial, for the optimal management of early stage HR+ breast cancer is discussed.
EP. 11: Early Stage HR+ Breast Cancer: Optimizing Multigene Assays
Aditya Bardia, MD, Massachusetts General Hospital Cancer Center
Hope S. Rugo, MD, leads the discussion on the new data presented at the 2021 ASCO annual meeting for MammaPrint and Breast Cancer Index for early stage HR+ breast cancer.
EP. 12: Using CDK4/6 Inhibitors in Early Stage HR+ Breast Cancer
Aditya Bardia, MD, Massachusetts General Hospital Cancer Center
Experts in breast cancer share insights on the role of CDK4/6 inhibition in the adjuvant setting for early stage HR+ breast cancer.
EP. 13: ES HR+ Breast Cancer: CDK4/6 Inhibitors in Clinical Practice
Aditya Bardia, MD, Massachusetts General Hospital Cancer Center
A discussion on the use of adjuvant CDK4/6 inhibitors in clinical practice for the treatment of early stage HR+ breast cancer.
EP. 14: Future Directions for the Management of HR+ Breast Cancer
Aditya Bardia, MD, Massachusetts General Hospital Cancer Center
Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.
